CD8A and neoplasm: Both RH-Δcps and RH-Δompdc preferentially invade immunosuppressive CD11c+ antigen-presenting cells and restore the ability to efficiently trigger CD8+ T-cell responses, showing great potential in the application of tumor immune-chemotherapeutic.